دورية أكاديمية
Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.
العنوان: | Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway. |
---|---|
المؤلفون: | Ikeda Z; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kamei T; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Sasaki Y; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Reynolds M; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Sakai N; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Yoshikawa M; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Tawada M; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Morishita N; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Dougan DR; Structural Biology, Takeda Development Center Americas, Inc., San Diego, California 92121, United States., Chen CH; Structural Biology, Takeda Development Center Americas, Inc., San Diego, California 92121, United States., Levin I; Structural Biology, Takeda Development Center Americas, Inc., San Diego, California 92121, United States., Zou H; Structural Biology, Takeda Development Center Americas, Inc., San Diego, California 92121, United States., Kuno M; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Arimura N; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kikukawa Y; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kondo M; Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan., Tohyama K; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Sato K; Research, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. |
المصدر: | Journal of medicinal chemistry [J Med Chem] 2023 May 11; Vol. 66 (9), pp. 6354-6371. Date of Electronic Publication: 2023 Apr 25. |
نوع المنشور: | Journal Article; Research Support, U.S. Gov't, Non-P.H.S. |
اللغة: | English |
بيانات الدورية: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Washington Dc : American Chemical Society Original Publication: [Easton, Pa.] : American Chemical Society, [c1963- |
مواضيع طبية MeSH: | Complement C1s*/chemistry , Complement C1s*/metabolism , Complement Activation*, Humans ; Serine Endopeptidases/metabolism ; Brain/metabolism |
مستخلص: | A novel series of non-amidine-based C1s inhibitors have been explored. Starting from high-throughput screening hit 3 , isoquinoline was replaced with 1-aminophthalazine to enhance C1s inhibitory activity while exhibiting good selectivity against other serine proteases. We first disclose a crystal structure of a complex of C1s and a small-molecule inhibitor ( 4e ), which guided structure-based optimization around the S2 and S3 sites to further enhance C1s inhibitory activity by over 300-fold. Improvement of membrane permeability by incorporation of fluorine at the 8-position of 1-aminophthalazine led to identification of ( R )-8 as a potent, selective, orally available, and brain-penetrable C1s inhibitor. ( R )-8 significantly inhibited membrane attack complex formation induced by human serum in a dose-dependent manner in an in vitro assay system, proving that selective C1s inhibition blocked the classical complement pathway effectively. As a result, ( R )-8 emerged as a valuable tool compound for both in vitro and in vivo assessment. |
References: | Bioorg Med Chem Lett. 2004 Jun 21;14(12):3043-7. (PMID: 15149641) J Biol Chem. 2005 Nov 25;280(47):39510-4. (PMID: 16169853) J Immunol. 2017 Dec 1;199(11):3883-3891. (PMID: 29061764) Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55. (PMID: 15299926) Expert Rev Clin Immunol. 2011 Mar;7(2):143-53. (PMID: 21426252) J Immunol. 2013 Apr 15;190(8):3839-47. (PMID: 23564578) Biomolecules. 2018 May 07;8(2):. (PMID: 29735903) Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. (PMID: 20383002) Bioorg Med Chem Lett. 2012 Aug 15;22(16):5303-7. (PMID: 22795627) Protein Cell. 2012 Jul;3(7):487-96. (PMID: 22773339) J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. (PMID: 19461840) Bioorg Med Chem Lett. 2013 Sep 15;23(18):5244-8. (PMID: 23845220) EMBO J. 2000 Apr 17;19(8):1755-65. (PMID: 10775260) Molecules. 2019 Oct 09;24(20):. (PMID: 31600984) Annu Rev Neurosci. 2012;35:369-89. (PMID: 22715882) Nat Rev Nephrol. 2012 Nov;8(11):643-57. (PMID: 23026949) Pharm Res. 2006 Jul;23(7):1460-72. (PMID: 16779700) J Med Chem. 2005 Sep 22;48(19):5900-8. (PMID: 16161994) Bioorg Med Chem Lett. 2008 Mar 1;18(5):1603-6. (PMID: 18242991) Immunobiology. 2002 Sep;205(4-5):383-94. (PMID: 12396001) Nat Rev Drug Discov. 2019 Sep;18(9):707-729. (PMID: 31324874) Nat Biotechnol. 2007 Nov;25(11):1256-64. (PMID: 17989688) Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32. (PMID: 20124692) Org Lett. 2016 May 6;18(9):2098-101. (PMID: 27101157) Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22. (PMID: 18156677) Nat Immunol. 2010 Sep;11(9):785-97. (PMID: 20720586) |
المشرفين على المادة: | EC 3.4.21.42 (Complement C1s) EC 3.4.21.- (Serine Endopeptidases) |
تواريخ الأحداث: | Date Created: 20230430 Date Completed: 20230512 Latest Revision: 20230629 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC10184130 |
DOI: | 10.1021/acs.jmedchem.3c00348 |
PMID: | 37120845 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1520-4804 |
---|---|
DOI: | 10.1021/acs.jmedchem.3c00348 |